BioBusiness

Feliza Mirasol is the science editor for 

Articles

Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.

Invitae and Deerfield Management Team Up on Novel Therapeutics for Rare Diseases

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.

Pfizer and Gero Form Collaboration to Discover Potential Targets for Fibrotic Diseases

The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.

AbbVie and Anima Biotech Partner on Discovery and Development of mRNA Biology Modulators

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

GSK and Wave Life Sciences to Collaborate on Oligonucleotide Therapeutics

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

AbCellera and Rallybio Partner on Novel Antibody-Based Therapeutics

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

Societal CDMO Signs Multiple CDMO Service Agreements

VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.

Partnerships